Skip to main content

Table 2 Characteristics of TB patients stratified according to types of lung lesions in Lima, Peru, 2017

From: Severe pulmonary radiological manifestations are associated with a distinct biochemical profile in blood of tuberculosis patients with dysglycemia

Characteristics

1 Type lesion

n = 39

2 Type lesions

n = 40

3 Type lesions

n = 53

p-value

Age (years)-median (IQR)

27.93 (22.75–31.92)

28.10 (22.04–49.06)

37.92 (24.58–47.64)

0.07

Sex

   

0.94

Male

23 (59.0)

25 (62.5)

33 (62.3)

 

Female

16 (41.0)

15 (37.5)

20 (37.7)

 

Education

   

0.12

Elementary and secondary school

25 (64.1)

29 (72.5)

44 (83.0)

 

Higher education

14 (35.9)

11 (27.5)

9 (17.0)

 

Prior TB

1 (2.6)

3 (7.5)

12 (22.6)

< 0.01

BCG vaccination

35 (89.7)

39 (97.5)

48 (92.3)

0.38

Smoking

7 (17.9)

13 (32.5)

8 (15.4)

0.12

Smoker at home

5 (12.8)

1 (2.5)

5 (9.6)

0.24

Cannabis use

6 (15.4)

8 (20.0)

6 (11.5)

0.54

Illicit drug use

3 (7.7)

7 (17.5)

6 (11.5)

0.41

Alcohol use

21 (53.8)

23 (57.5)

23 (44.2)

0.42

Hypertension

1 (2.6)

3 (7.5)

3 (5.8)

0.61

Asthma

4 (10.3)

1 (2.5)

2 (3.8)

0.26

Renal disease

0 (0.0)

1 (2.5)

1 (1.9)

0.64

Slow scarring

6 (15.4)

5 (12.5)

8 (15.4)

0.91

Metformin use

0 (0.0)

2 (5.3)

5 (9.8)

0.13

BMI (kg/m2)-median (IQR)

23.53 (21.22–25.08)

22.28 (20.08–25.39)

22.66 (20.19–25.68)

0.28

Waist circumference (cm) -median (IQR)

84 (76–90)

81 (75–86)

82 (77–89)

0.34

Hemoglobin (g/dL) -median (IQR)

12.60 (11.50–13.30)

12.15 (10.85–13.53)

11.25 (10.53–12.65)

0.03

FPG (mg /dL) -median (IQR)

91.5 (7.3)

100.4 (36.3)

140.9 (91.7)

< 0.01

HbA1c (%)- median (IQR)

4.9 (0.41)

5.2 (0.8)

6.9 (3.2)

< 0.01

OGTT (mg/dL) -median (IQR)

113.4 (29.9)

109.8 (26.7)

115.0 (28.6)

0.76

AFB smear

   

0.04

Negative

23 (59.0)

17 (43.6)

17 (32.1)

 

1+

8 (20.5)

7 (17.9)

12 (22.6)

 

2+

1 (2.6)

6 (15.4)

7 (13.2)

 

3+

6 (15.4)

7 (17.9)

15 (28.3)

 

Scanty

1 (2.6)

2 (5.1)

2 (3.8)

 

L-J culture

   

< 0.01

Negative

14 (36.8)

16 (43.2)

6 (11.5)

 

1+

18 (47.4)

14 (37.8)

29 (55.8)

 

2+

1 (2.6)

4 (10.8)

4 (7.7)

 

3+

1 (2.6)

2 (5.4)

4 (7.7)

 

Colonies

4 (10.5)

1 (2.7)

9 (17.3)

 

BD MGIT™ 960 System

   

0.43

Positive

18 (81.8)

13 (65.0)

33 (97.1)

 

Negative

4 (18.2)

7 (35.0)

1 (2.9)

 

MDR

3 (14.3)

2 (12.5)

4 (10.3)

0.90

Isoniazid -resistant

4 (19.0)

2 (12.5)

8 (20.5)

0.78

Rifampicin -resistant

4 (19.0)

3 (18.8)

4 (10.3)

0.57

Cough for more than 4 weeks

33 (84.6)

37 (92.5)

50 (94.3)

0.26

Hemoptysis

15 (38.5)

17 (42.5)

23 (43.4)

0.89

Fever

21 (53.8)

18 (45.0)

22 (41.5)

0.50

Dyspnea

29 (74.4)

27 (67.5)

30 (56.6)

0.20

Night sweats

20 (51.3)

22 (55.0)

33 (62.3)

0.56

No appetite

23 (59.0)

26 (65.0)

31 (58.5)

0.79

Lost weight

28 (71.8)

29 (72.5)

40 (75.5)

0.91

Fatigue

30 (76.9)

29 (72.5)

44 (83.0)

0.47

Polyuria

15 (38.5)

13 (32.5)

23 (43.4)

0.57

Polydipsia

16 (41.0)

21 (52.5)

26 (49.1)

0.58

  1. Data represent no. (%); IQR Interquartile range. BCG Bacillus Calmette–Guérin, BMI Body Mass Index, Hb Hemoglobin, FPG Fasting Plasma Glucose, HbA1c Glycated Hemoglobin, OGTT Oral Glucose Tolerance Test, AFB Acid-Fast Bacilli, L-J Löwenstein-Jensen, MDR Multi Drug Resistant. Hypertension, asthma, renal disease and anemia as defined by the World Health Organization as described in Methods. Prior TB: diagnosis of active tuberculosis before of this